Dalton Pharma Services completes $5 million expansion

The project was supported by CA$2.085 million of funding from FedDev Ontario

Dalton has created around 20 new skilled life sciences jobs at its sterile filling and API manufacturing operation

Dalton Pharma Services, a privately owned Canadian contract development and manufacturing organisation, has completed a $5 million expansion in sterile filling and API manufacturing at its cGMP facility in Toronto.

The firm, which offers manufacturing, chemistry and analytical services on a contract basis to the global pharmaceutical and biotechnology industries, has added three new sterile processing suites and an active pharmaceutical ingredient (API) manufacturing suite.

A semi-automated powder filling line with significant scale-up of lyophilisation capacity is also included.

The firm has also increased its analytical capabilities, its chemistry capacity, and has made facility upgrades to meet sterile manufacturing GMP API standards.

Approximately 20 new skilled life sciences jobs have been created over the past year.

The project was supported by CA$2.085 million of funding through FedDev Ontario's Investing in Business Growth and Productivity Initiative, which aims to help established businesses to expand their operations, invest in productivity improvements and compete globally.

Dalton has completed a $5 million expansion of its sterile filling and API manufacturing operation

Combined with the company’s own investment of $3.5 million, the expansion project brings the total investment at the site to more than $5 million.

With the expansion and improvements to its sterile manufacturing facility Dalton Pharma Services aims to meet growing demand for preclinical development and small/medium clinical trial batches for commercial production, for both API and sterile finished doses.

'Increasing sterile filling capability and capacity for both powders and liquids has been a key part of our plan for strategic growth,' said Peter Pekos, President and CEO.

'Completion of this expansion is a major step designed to meet the increasing global demand for sterile filling development and production, and supports the integrated drug development and manufacturing we offer our clients.'

Dalton's full range of services in-house include drug discovery, flow chemistry, formulation and process development, custom synthesis, cGMP sterile fill/finish, cGMP API manufacturing and/or dosage form manufacturing, all at one location.

Companies